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Abstract
Background: Spermidine is a dietary polyamine that is able to activate protein tyrosine phosphatase non-receptor type 2
(PTPN2). As PTPN2 is known to be a negative regulator of interferon-gamma (IFN-c)-induced responses, and IFN-c
stimulation of immune cells is a critical process in the immunopathology of inflammatory bowel disease (IBD), we wished to
explore the potential of spermidine for reducing pro-inflammatory effects in vitro and in vivo.
Methods: Human THP-1 monocytes were treated with IFN-c and/or spermidine. Protein expression and phosphorylation
were analyzed by Western blot, cytokine expression by quantitative-PCR, and cytokine secretion by ELISA. Colitis was
induced in mice by dextran sodium sulfate (DSS) administration. Disease severity was assessed by recording body weight,
colonoscopy and histology.
Results: Spermidine increased expression and activity of PTPN2 in THP-1 monocytes and reduced IFN-c-induced
phosphorylation of signal transducer and activator of transcription (STAT) 1 and 3, as well as p38 mitogen-activated protein
kinase (MAPK) in a PTPN2 dependent manner. Subsequently, IFN-c-induced expression/secretion of intracellular cell
adhesion molecule (ICAM)-1 mRNA, monocyte chemoattractant protein (MCP)-1, and interleukin (IL)-6 was reduced in
spermidine-treated cells. The latter effects were absent in PTPN2-knockdown cells. In mice with DSS-induced colitis,
spermidine treatment resulted in ameliorated weight loss and decreased mucosal damage indicating reduced disease
severity.
Conclusions: Activation of PTPN2 by spermidine ameliorates IFN-c-induced inflammatory responses in THP-1 cells.
Furthermore, spermidine treatment significantly reduces disease severity in mice with DSS-induced colitis; hence,
spermidine supplementation and subsequent PTPN2 activation may be helpful in the treatment of chronic intestinal
inflammation such as IBD.
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Introduction
Inflammatory Bowel Diseases (IBD) is a group of complex,
chronic intestinal inflammatory disorders with unknown etiology,
including Crohn’s Disease (CD) and ulcerative colitis (UC). IBD
patients suffer from recurrent or chronic gastrointestinal symp-
toms, including diarrhea, abdominal pain, bleeding, anemia and
weight loss. Additionally, a spectrum of extraintestinal manifesta-
tions, such as joint inflammation, skin and eye manifestations or
primary sclerosing cholangitis, may be associated with these
diseases. Conventional therapies (e.g. aminosalicylates, antibiotics,
corticosteroids and immunosuppressants) as well as biologicals (e.g.
anti-tumour necrosis factor (TNF) and anti-integrin antibodies) are
available to treat CD and UC. However, side effects of these
treatments are often severe and loss of response over time is
common [1,2], indicating an urgent need for developing novel
strategies to treat IBD.
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Although the pathogenesis of IBD is not completely understood,
a well-accepted hypothesis is that dysregulation of the mucosal
immune response against normal intestinal microbiota in genet-
ically susceptible individuals contributes to the development of the
disease [3,4]. Data from genome-wide association studies have
identified more than 140 genetic loci that confer susceptibility for
IBD [5]. Among them is the gene locus encoding protein tyrosine
phosphatase non-receptor type 2 (ptpn2) [6,7,8]. PTPN2, also
known as ‘‘T-cell protein tyrosine phosphatase’’, is an intra-
cellular tyrosine-specific phosphatase, which is expressed in
epithelial cells, fibroblasts or endothelial cells featuring particularly
high expression in hematopoietic tissues [9]. Two splice variants of
PTPN2 are present in human cells: a 48 kDa form which is
located in the endoplasmic reticulum, and a 45 kDa variant which
is predominantly found in the nucleus. The nuclear variant
translocates to the cytoplasm in response to pro-inflammatory
stimuli such as interferon-gamma (IFN-c), epidermal growth factor
(EGF), hyperosmotic stress or starvation [10]. Several phosphor-
ylated proteins are well known targets of dephosphorylation by
PTPN2, including the epidermal growth factor receptor [11],
vascular endothelial growth factor receptor-2 [12], the insulin
receptor [13], signal transducers and activators of transcription 1
and 3 (STAT1 and STAT3) [14,15], and mitogen-activated
protein kinase (MAPK)-isoforms, such as p38 [16]. Inactivation of
those substrates by dephosphorylation results in the negative
regulation of signaling pathways involved in inflammatory
responses induced by the pro-inflammatory cytokines IFN-c
[17,18], TNF [19] and interleukin (IL)-6 [14].
Spermidine is a positively charged polyamine, present in high
quantities in foods including mushrooms, peas, cashews, and some
types of meat and cereals [20]. Because of its role in cell growth,
survival and proliferation [21,22], spermidine supplementation is
being tested to treat conditions in which regeneration and healing
are needed, such as impaired liver function, liver resection or burn
injury [21,23]. A role of polyamines in inflammatory responses has
also been suggested. Specifically, it has been shown that
spermidine is able to increase the phosphatase activity of PTPN2
in vitro in multiple cell lines including HeLa cells and human
umbilical vein endothelial cells (HUVEC) [24]. Given the reported
function of PTPN2 as a negative regulator of pro-inflammatory
cytokine signaling [17,19,25], we hypothesized that pharmacolog-
ical activation of PTPN2 by spermidine could potentially
ameliorate pro-inflammatory responses induced by cytokines. To
test our hypothesis, we first analyzed the effects of spermidine on
IFN-c-induced pro-inflammatory signaling and cytokine produc-
tion in human THP-1 monocytes. Monocytes/macrophages, as
part of the innate immune system of the gut mucosa, play an
important role in the pathogenesis of IBD [26]. We found that the
activation of PTPN2 by spermidine negatively regulated IFN-c-
induced signaling and cytokine secretion in THP-1 cells,
conferring protection against the inflammatory responses induced
by this cytokine. Subsequently, the therapeutic effect of spermidine
was investigated in vivo using an experimental model of colitis. In
mice with dextran sodium sulfate (DSS)-induced colitis, disease
activity was reduced upon treatment with spermidine, supporting
its anti-inflammatory potential as a therapy to treat IBD.
Methods
Induction of Colitis and Spermidine Treatment in Mice
Animal experiments were carried out according to Swiss animal
welfare laws and were approved by the veterinary authorities of
Zurich, Switzerland (Kanton Zu¨rich Gesundheitsdirektion Veter-
ina¨ramt, approval no. 54/2011). Due to the approval of the
veterinary authorities of Zu¨rich, no further approval by an
Institutional Animal Care and Use Committee (IACUC) or ethics
committee was necessary. Seven- to eight-week-old female
C57BL/6J-Crl mice were used for the experiments and housed
in a specified pathogen-free facility in individually ventilated cages.
Acute colitis was induced with 2.5% DSS (MP Biomedicals,
Illkirch, France) in drinking water during 8 days [27]. The animals
were randomly divided into two DSS groups and two water
control groups with six individuals each. For treatment, spermi-
dine was dissolved in water at 0.1 M and 150 ml administered by
oral gavage. The non-treated control groups received 150 ml of
water by oral gavage. Food and water were available ad libitum.
Assessment of Colonoscopy and Histological Score in
Mice
Animals were anesthetized intraperitoneally with 90–120 mg/
kg body weight ketamine (Ve´toquinol, Bern, Switzerland) and
8 mg/kg body weight xylazine (Bayer, Lyssach, Switzerland).
Animals were examined as described previously [28]. Briefly, the
solid endoscope was introduced per anus with a lubricant (2%
lidocaine) in the sedated mouse. The colon was gently inflated with
air. Recording was performed with the Karl Storz Tele Pack Pal
20043020 (Karl Storz Endoskope, Tuttlingen, Germany). Colo-
noscopy was scored using the murine endoscopic index of colitis
severity (MEICS) scoring system as described previously [28]. In
detail, the MEICS score was assessed as follows: The MEICS
consisted of five parameters, as indicated: (1) Thickening of the
colon (transparent, moderate, marked, non-transparent 0–3
points), (2) changes of the vascular pattern (normal, moderate,
marked, bleeding, 0–3 points), (3) fibrin visible (none, little,
marked, extreme 0–3 points), (4) granularity of the mucosal surface
(none, moderate, marked, extreme 0–3 points) and (5) stool
consistency (normal+solid, still shaped, unshaped, spread 0–3
points). The overall score range is then between 0–15. After
colonoscopy, all animals were sacrificed by cervical dislocation.
Histological scoring for inflammatory infiltration and epithelial cell
damage was performed on H&E stained section of the most distal
1 cm of the mouse colon as described previously [27,28].
Myeloperoxidase (MPO) Activity Assay
Colon specimens were rinsed with PBS and homogenized
mechanically in 50 mM phosphate buffer (pH 6.0) and 0.5%
hexadecyltrimethylammonium bromide (Sigma Aldrich) with a
tissuelyzer (Qiagen). After three freeze and thaw cycles, homog-
enates were centrifuged for 2 min at 17,000 g. 20 ml of the
supernatant were transferred to a 96-well plate in duplicate and
mixed with 280 ml of 0.02% dianisidine (in 50 mM phosphate
buffer, pH 6.0, and 0.0005% H2O2; Sigma Aldrich). After 20 min,
absorbance was measured at 460 nm. Protein concentration of the
supernatant was determined by bicinchoninic acid protein assay.
Myeloperoxidase activity, expressed as arbitrary units, was
calculated as mean absorbance (460 nm) per incubation time (in
min) per protein concentration (in g).
Antibodies
The monoclonal mouse anti-PTPN2 antibody CF-4 that detects
the 45 kDa and the 48 kDa isoforms and the monoclonal mouse
anti-protein tyrosine phosphatase 1B (PTP1B) AE4 antibody were
obtained from Calbiochem (San Diego, CA). Mouse anti-b-actin
antibody was purchased from EMD Millipore (Billerica, MA).
Rabbit anti-phospho-STAT1 (Tyr701), rabbit anti-STAT1, rabbit
anti-phospho-STAT3 (Tyr705), rabbit anti-STAT3, mouse anti-
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phospho-p38 (Thr180/Tyr182) and rabbit anti-p38 antibodies
were obtained from Cell Signaling Technologies (Danvers, MA).
Cell Culture
Human monocytic THP-1 cells were cultured in a humidified
atmosphere with 5% CO2 in RPMI 1640 medium (Life
Technologies Ltd, Paisley, UK) containing 10% fetal calf serum
(VWR International, Radnor, PA). Before treatment with
recombinant human IFN-c (1000 U/ml; Roche, Basel, Switzer-
land) and/or spermidine (100 mM; Merck, Darmstadt, Germany),
56105 cells were seeded for 2 days in 24-well plates (Techno
Plastic Products AG, Trasadingen, Switzerland).
Preparation of Whole Cell Lysates
After treatment, THP-1 cells were kept on ice. Cells were
washed twice with phosphate buffered saline (PBS) and lysed in M-
Per Mammalian protein extraction reagentH (Pierce Biotechnol-
ogy, Rockford, IL) supplemented with the protease inhibitor
cocktail tablets ‘‘Complete miniH’’ (Roche) for 30–45 min. Cells
were then centrifuged for 10 min at 13,000 g, and supernatants
were collected. Protein concentration was quantified by UV280 nm
using a NanoDrop ND1000 (Thermo Scientific, Waltham, MA).
RNA Isolation and Real-time Polymerase Chain Reaction
Total RNA was isolated using an RNeasyH Mini Kit (Qiagen,
Du¨sseldorf, Germany) and a QIA-Cube automated sample
preparer (Qiagen). RNA concentration was determined by
UV260 nm using a NanoDrop ND1000 (Thermo Scientific). cDNA
synthesis was performed using a High-Capacity cDNA Reverse
Transcription Kit (Life Technologies Ltd). Real-time PCR was
performed using TaqMan Gene Expression Assays (Life Technol-
ogies Ltd) and TaqMan Fast Universal PCR Master Mix No
AmpErase UNG (Life Technologies Ltd) on a 7900 HT Fast Real-
Time PCR System with SDS 2.2 Software (Life Technologies Ltd).
Measurements were performed in triplicates, using the gene for
human b-actin as an endogenous control.
Phosphatase Activity Assay
Phosphatase activity was assessed using the EnzChekH Phos-
phatase Assay Kit (Life Technologies Ltd) according to the
manufacturer’s instructions and as described previously [18].
Western Blot
Proteins were separated by SDS-polyacrylamide gel electro-
phoresis and transferred onto nitrocellulose membranes (Life
Technologies Ltd). Membranes were blocked overnight with
blocking solution (Tris-buffered saline containing 1% Tween 20
supplemented with 5% bovine serum albumin), and incubated
with the diluted primary antibody (concentrations according to the
manufacturers instructions) in blocking solution for an appropriate
time. Membranes were washed with washing solution (blocking
solution without bovine serum albumin) for 1 h, and then
incubated with horseradish peroxidase (HRP)-labelled secondary
anti-mouse-, anti-goat- or anti-rabbit-IgG-antibody (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) diluted (1:3000) in blocking
solution for up to 30 min. Finally, membranes were washed for
1 h with washing solution and immunoreactive proteins were
detected using an enhanced chemiluminescence detection kit (GE
Healthcare, Little Chalfont, UK). Densitometric analysis of
Western blots was performed using the National Institutes of
Health (NIH) Image software.
Small Interfering RNA (siRNA) Transfection
THP-1 cells were seeded 3 days before transfection to a density
of 46105 cells per T75 flask. Three different annealed silencer pre-
designed siRNA oligonucleotides targeting the ptpn2 gene were
obtained from Life Technologies Ltd. Per transfection, 100 pmol
of each of the three gene specific siRNA oligonucleotides were
transfected into THP-1 cells using the Amaxa nucleofector system
(Lonza, Walkersville, MD) according to the manufacturer’s
instructions resulting in a final siRNA concentration of 1 nMol/
ml. The achieved PTPN2 knock.-down was about 70%.
After transfection, THP-1 cells were cultured in a 24-well plate
for 36 h before treatment. Non-specific control siRNA (100 pmol/
transfection, Life Technologies Ltd) was used as negative control.
Enzyme-linked Immunosorbent Assay (ELISA)
Supernatants from THP-1 cell cultures were collected and
stored at 280uC until further analysis. ELISA kits for detection of
human IL-6, and human monocyte chemoattractant protein
(MCP)-1 were obtained from R&D Systems (Minneapolis, MN).
Assays were performed according to the manufacturer’s instruc-
tions. Absorbance at 450 nm was determined using a BioTek
Synergy 2 Microplate reader with Gen 5 Software version 5.1.11
(BioTek Instruments, Inc., Winooski, VT). Measurements were
performed in duplicates.
Statistical Analysis
Data are presented as means 6 standard deviations for a series
of n experiments. Statistical analysis was performed by analysis of
variance (ANOVA) followed by the Student–Newman–Keuls (for
cell-line based experiments) or Mann-Whitney U (for mouse
experiments) post hoc test. P values ,0.05 were considered
significant.
Results
Spermidine Treatment Induces PTPN2 Protein Expression
in Human Monocytic THP-1 Cells
Because PTPN2 is crucially involved in negatively regulating
IFN-c induced signaling [17], we hypothesize that continuous
pharmacological activation of PTPN2 by spermidine could
attenuate the pro-inflammatory signaling induced by this cytokine.
We thus investigated if PTPN2 activity and/or expression can be
enhanced by spermidine in THP-1 monocytes and if this would
attenuate the pro-inflammatory response to IFN-c in these cells.
To address the effect of spermidine on PTPN2 expression, THP-1
cells were incubated in the presence of IFN-c and/or spermidine
for 30 min or 36 h, and lysates were analyzed by Western blot
using a monoclonal antibody specific for PTPN2. As shown in
Figure 1a, neither IFN-c nor spermidine treatment resulted in an
increase in PTPN2 protein levels after 30 min. However, there
was a significant increase in PTPN2 levels in both IFN-c or
spermidine treated cells after 36 h treatment, but co-stimulation
had no additive effect (Figure 1b).
To investigate the specificity of spermidine for PTPN2, we
additionally analyzed the protein expression of PTP1B, a closely
related phosphatase that also regulates IFN-c-induced responses
[29]. In contrast to the observed increase in PTPN2 expression,
neither IFN-c nor spermidine treatment changed the expression
levels of PTP1B (Figures 1c and 1d). Taken together, this indicates
that both IFN-c and spermidine specifically induce PTPN2
expression after 36 h treatment.
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Spermidine Treatment Increases Phosphatase Activity of
PTPN2 in Human Monocytic THP-1 Cells
To further explore the effects of spermidine on PTPN2 in human
THP-1 cells, we measured the phosphatase activity of PTPN2 in
response to treatment with IFN-c and/or spermidine by performing
immunoprecipitation of PTPN2 from whole cell lysates and
analyzing its phosphatase activity using a fluorescence-based assay.
As shown in Figure 2a, a significant increase in PTPN2 phosphatase
activity was observed after treatment of cells for 30 min with
spermidine or with IFN-c and spermidine (p,0.01 and p,0.001,
respectively), compared to untreated cells or IFN-c-treated cells.
This indicates that spermidine increases enzymatic activity of
PTPN2 at a time point in which protein expression is not affected
(Figure 1a). However, at this time point co-treatment with
spermidine and IFN-c did not have a statistically significant additive
effect on PTPN2 activity, compared to treatment with spermidine or
IFN-c alone. When cells were incubated for 36 h, IFN-c alone was
able to significantly increase the phosphatase activity of PTPN2
(p,0.001; Figure 2b), which is consistent with our previous results
[18]. Moreover, cells treated with spermidine alone showed
significantly increased PTPN2 activity at 36 h, with nearly a 3-fold
induction compared to untreated cells (p,0.001, Figure 2b). The co-
treatment of THP-1 cells with both IFN-c and spermidine for 36 h
significantly further increased PTPN2 phosphatase activity, com-
Figure 1. Effect of spermidine and interferon-gamma (IFN-c) treatment on protein tyrosine phosphatases (PTPN2 and PTP1B)
expression in humanmonocytic THP-1 cells. THP-1 cells were treated with IFN-c (1000 U/ml) and/or spermidine (100 mM) for (a, c) 30 min or (b,
d) 36 h. Whole-cell lysates were obtained and PTPN2 and PTP1B protein levels were analyzed by Western blot using b-actin as a loading control. The
relative protein levels were assessed by densitometry (n = 3). Data are expressed as fold induction with respect to untreated cells. Asterisks indicate
significant differences between treated and untreated cells (* = p,0.05, ** = p,0.01).
doi:10.1371/journal.pone.0073703.g001
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pared to either IFN-c or spermidine alone (p,0.01 and p,0.05,
respectively; Figure 2b). This observation clearly indicates an
additive effect of both stimuli at this time point with respect to
PTPN2 phosphatase activity, effect that was not observed on protein
expression (Figure 1b). Because phosphatase activity was normal-
ized to the PTPN2 protein content of the cells, the observed increase
in activity is not due to the increase in PTPN2 protein level, but
rather to actual activation of the available PTPN2 protein, and
appears to occur independently of the increase in PTPN2 expression
levels.
Repetitive Administration of Spermidine Causes
Persistent PTPN2 Activation in Human Monocytic THP-1
Cells
Because spermidine may be metabolized by the cells and
disappear rapidly from the media, and in order to explore the
effects of dosing intervals for future preclinical investigations, we
measured the change in phosphatase activity of PTPN2 over time
after a single dose or after multiple doses of spermidine in THP-1
cells. Cells were incubated with spermidine for up to 72 h, adding
the polyamine either once at 0 h or three times at intervals of 24 h.
Phosphatase activity was measured at 0 h, 12 h, 24 h, 48 h, and
72 h. As shown in Figure 3, PTPN2 phosphatase activity reached
the maximum value (,4-fold the basal value) 24 h after
spermidine treatment. Even without further spermidine treatment,
PTPN2 activity was maintained at this maximum level for an
additional 24 h. However, whereas the effects of a single dose of
spermidine were observed to wear off between 48 and 72 h, dosing
of additional spermidine every 24 h was effective, with even a
slight further increase in PTPN2 activity after each spermidine
administration over the 72 h testing period. We then measured
PTPN2 protein at 48 and 72 h in response to spermidine
treatment of THP-1 cells. We found that the spermidine-induced
increase in PTPN2 enzymatic activity is reflected by an increase in
spermidine-induced PTPN2 protein level over time. Interestingly,
repeated treatment with spermidine (every 24 h) causes a further
increase in PTPN2 protein level compared to single spermidine
treatment (Figure 4). These findings indicate that administration of
repetitive doses of spermidine every 24 to 48 h was effective in
maintaining PTPN2 activity and even further induced PTPN2
protein level. This dosing schedule is a reasonable starting point
for performing pharmacokinetic and pharmacodynamic preclin-
ical studies to determine the appropriate clinical dosing schedule.
PTPN2 Activation by Spermidine Ameliorates IFN-c-
induced Phosphorylation of STAT1, STAT3 and p38
After demonstrating that spermidine is able to induce PTPN2
protein expression and phosphatase activity in THP-1 monocytes,
we next studied the functional relevance of this observation.
Previous studies found STAT1, STAT3, and p38 to be PTPN2
dephosphorylation targets [14,15,16,30], and indicated that loss of
PTPN2 activity causes increased activation of STAT1, STAT3,
and p38 in IFN-c-treated THP-1 cells [17]. Thus, we explored
whether the induction of the expression and activity of PTPN2 by
spermidine results in reduced activation (as monitored by
phosphorylation status) of its targets STAT1, STAT3 and p38.
As expected, treatment of THP-1 cells with IFN-c for 30 min
markedly increased the phosphorylation of STAT1 (p,0.001;
Figure 5a). Co-administration of spermidine significantly reduced
IFN-c-induced STAT1 phosphorylation (p,0.001). Similar results
were found for STAT1 in cells treated for 36 h (Figure 5b), with
significantly increased phosphorylation of STAT1 in cells treated
with IFN-c (p,0.001), which was reduced upon co-treatment with
spermidine (p,0.001). Comparable findings were also observed
for STAT3 and p38 phosphorylation for cells treated with
spermidine for 30 min. As shown in Figure 5c and 5d, IFN-c
increased phosphorylation of both STAT3 and p38 (p,0.001).
Spermidine administration diminished the phosphorylation of
STAT3 and p38 induced by IFN-c in THP-1 cells compared to
cells only treated with IFN-c (p,0.001 and p,0.01, respectively).
These findings demonstrate that PTPN2 activation by spermidine
is able to reduce downstream pro-inflammatory signal transduc-
tion events induced by IFN-c in human THP-1 monocytes.
Figure 2. Protein tyrosine phosphatase non-receptor type 2 (PTPN2) phosphatase activity in interferon-gamma (IFN-c)- and/or
spermidine-treated human monocytic THP-1 cells. THP-1 cells were treated with IFN-c (1000 U/ml) and/or spermidine (100 mM) for (a) 30 min
or (b) 36 h. PTPN2 was immunoprecipitated from whole-cell lysates and phosphatase activity was measured (n = 3). Blots were probed for PTPN2 to
show equivalent protein levels. Data are expressed as fold induction with respect to untreated cells. Significant differences compared to untreated
cells (** = p,0.01, *** = p,0.001), compared to cells treated with IFN-c only (##=p,0.01, ###=p,0.001), or compared to cells treated with
spermidine alone (x = p,0.05) are indicated.
doi:10.1371/journal.pone.0073703.g002
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Figure 3. Changes in protein tyrosine phosphatase non-receptor type 2 (PTPN2) phosphatase activity after spermidine treatment
of human monocytic THP-1 cells. THP-1 cells were incubated with (white symbols) or without (black symbols) spermidine (100 mM) for 72 hours.
For spermidine treated cells, the polyamine was either added once at 0 h (white circles) or every 24 h (white triangles). PTPN2 was
immunoprecipitated from whole-cell lysates, and phosphatase activity was measured (n = 3). Data are expressed as fold induction with respect to
untreated cells. Asterisks indicate a significant difference between phosphatase activity at the 72 h time point for the two spermidine treatments
(** = p,0.01).
doi:10.1371/journal.pone.0073703.g003
Figure 4. THP-1 cells were incubated with (white bars) or without (black bars) spermidine (100 mM) for 72 hours. For spermidine
treated cells, the polyamine was either added once at 0 h or every 24 h as indicated. The cells were harvested at the indicated time points
and analyzed for PTPN2 expression (n = 3). Significant differences from the respective controls are denoted by asterisks (* = p,0.05, *** = p,0.05).
doi:10.1371/journal.pone.0073703.g004
PTPN2 Activation by Spermidine Ameliorates Colitis
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PTPN2 Activation by Spermidine Reduces Secretion and
Expression of STAT1 and p38-MAPK-dependent Pro-
inflammatory Cytokines in THP-1 Cells
To determine the effects of spermidine on the activation of
IFN-c-induced signal transducers as well as on the synthesis of
IFN-c-induced cytokines, we next measured the gene expression
and secretion of STAT1 and p38-MAPK-dependent cytokines
in THP-1 cells. As shown in Figure 5a and consistent with
previous results [17], IFN-c treatment significantly increased
mRNA expression of intracellular cell adhesion molecule
(ICAM)-1 (p,0.001). Spermidine co-treatment for 24 h reduced
IFN-c-stimulated mRNA expression of ICAM-1 (p,0.01;
Figure 5. Effects of spermidine treatment on the phosphorylation levels of signal transducers and activators of transcription
(STATs) and p38 mitogen-activated protein kinase (MAPK) in interferon-gamma (IFN-c)-treated THP-1 cells. Representative Western
blots and densitometry (n = 3) show phosphorylation status of (a and b) STAT1, (c) STAT3 and (d) p38 MAPK in THP-1 cells treated with IFN-c
(1000 U/ml) and/or spermidine (100 mM) for (a, c, and d) 30 min or (b) 36 h. Blots were probed for b-actin to show equal protein loading. Significant
differences compared to untreated cells (* = p,0.05, ** = p,0.01, *** = p,0.001) or compared to cells treated with IFN-c only (##=p,0.01,
###=p,0.001) are indicated.
doi:10.1371/journal.pone.0073703.g005
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Figure 6a), whereas spermidine treatment alone had no
significant effect on ICAM-1 mRNA levels (Figure 6a). We
then tested whether PTPN2 activation by spermidine alters the
amount of cytokines secreted by THP-1 cells. As shown in
Figure 6b, incubation for 24 h with IFN-c markedly induced
the secretion of IL-6 (p,0.001). This effect was clearly reduced
after spermidine co-treatment of cells (p,0.001). Similarly,
spermidine was able to ameliorate the IFN-c-induced secretion
of MCP-1 from THP-1 cells (p,0.001; Figure 6c). These data
demonstrate that spermidine treatment reduces pro-inflamma-
tory gene expression and cytokine secretion induced by IFN-c
in THP-1 cells and support the hypothesis of an anti-
inflammatory effect of spermidine.
Anti-inflammatory Effects of Spermidine are Dependent
on PTPN2
To confirm that the decrease in the secretion of IFN-c-induced
cytokines after spermidine treatment was mediated by PTPN2, we
quantified the levels of MCP-1 and IL-6 secreted by PTPN2-
knockdown cells treated with IFN-c and/or spermidine. THP-1
monocytes were transfected with either siRNA oligonucleotides
targeting ptpn2 or with nonspecific siRNA sequences as a control,
and treated with IFN-c and/or spermidine for 24 h. As shown in
Figure 7a, spermidine treatment markedly reduced the IFN-c-
induced secretion of MCP-1 in cells transfected with non-specific
siRNA (p,0.05), whereas no significant reduction was observed in
PTPN2-knockdown cells treated with spermidine and IFN-c.
Additionally, incubation of cells with spermidine significantly
reduced IL-6 secretion induced by IFN-c in cells transfected with
non-specific siRNA (p,0.01), whereas this effect was absent in
PTPN2-deficient cells (Figure 7b). Taken together, these results
show that the observed reduction of IFN-c-induced cellular
responses by spermidine treatment of THP-1 cells is mediated
by PTPN2.
Spermidine Treatment Reduces Weight Loss and
Ameliorates Mucosal Damage in Mice with DSS-induced
Colitis
To investigate the anti-inflammatory potential of spermidine
in vivo, acute colitis was induced in mice by adding 2.5% DSS in
the drinking water. During the induction of colitis, one group of
mice was treated daily with spermidine by oral gavage, while the
other group received oral gavages with water. Control groups
received no DSS and oral gavages with either spermidine or water.
As expected, DSS treatment induced a significant weight loss
when compared to that in water-fed mice (Figure 8a). While
spermidine treatment had no effect on body weight in water-fed
mice, it significantly reduced weight loss in DSS-treated mice
(p,0.05; Figure 7a). To assess whether the differences in weight
loss correlated with macroscopic signs of inflammation, colonos-
copy was performed on day 8 of DSS treatment (Figure 8b), and
the results were evaluated using MEICS score (Figure 8c). As
shown in Figure 8b, no signs of inflammation could be detected in
control animals and solid stool pellets were visible. In DSS-treated
mice however, thickened mucosa with granular appearance and
non-transparent bowel wall, altered or even invisible vascular
pattern with occasional bleeding, and smeary stool was observed,
indicative for severe mucosal inflammation. Spermidine treatment
alone did not change the macroscopic appearance of the bowel in
water-fed mice. In DSS-treated mice however, spermidine
administration reduced the severity of inflammation: when
compared to mice receiving only DSS, the loss of transparency
of the bowel wall was less pronounced with reduced granularity,
the vascular pattern appeared more normal and no bleeding was
detectable (Figure 8b). Evaluation of colonoscopic results using
MEICS score showed a significant reduction of DSS-induced
intestinal damage in mice treated with spermidine compared to
those treated with water (p,0.01; Figure 8c). This indicates that
spermidine treatment reduces DSS-induced weight loss and
colonic damage in mice.
Spermidine Administration Decreased DSS Mediated
Inflammatory Infiltration and Epithelial Damage in Mouse
Colon
To assess the extent of microscopic damage, histological analysis
of colonic tissue specimen was performed. The mucosa of mice
receiving either water or spermidine, showed regular crypt
architecture and no signs of inflammation (Figures 9a and b). As
expected, DSS treatment induced a severe inflammatory response
with an almost complete loss of crypts, strong infiltration of
Figure 6. Cytokine signaling in interferon-gamma (IFN-c)- and/or spermidine-treated THP-1 cells. The graphs show (a) mRNA levels of
intracellular cell adhesion molecule (ICAM)-1, (b) secretion of interleukin (IL)-6, and (c) secretion of monocyte chemoattractant protein (MCP)-1 in
THP-1 cells treated with IFN-c (1000 U/ml) and/or spermidine (100 mM) for 24 h (n = 3). Data are expressed as fold induction with respect to untreated
cells. Significant differences compared to untreated cells (** = p,0.01, *** = p,0.001) or compared to IFN-c-treated cells (##=p,0.01,
###=p,0.001) are indicated.
doi:10.1371/journal.pone.0073703.g006
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lymphocytes in both mucosa and submucosa, and thickening of
the bowel wall (Figure 9c). In DSS-treated mice receiving
spermidine, however, the loss of crypts was less pronounced and
infiltration of inflammatory cells was reduced when compared to
mice receiving DSS alone (Figures 9c and 9d). Histological scoring
for inflammatory infiltrates and epithelial damage corroborated
these findings (Figures 9e–g), indicating that spermidine treatment
reduces epithelial damage and inflammatory infiltration in mice
with DSS induced colitis. Further, we assessed additional
indicators of colitis such as colon length and MPO activity. DSS
treatment induced a shortening of the colon in both spermidine
treated and non-treated animals, however the shortening was
significantly less pronounced in mice receiving spermidine
(Figure 10a). In addition, the DSS-induced increase in MPO
activity, a marker of neutrophil infiltration, was significantly lower
in mice treated with spermidine compared to those treated with
Figure 7. Effect of protein tyrosine phosphatase non-receptor
type 2 (PTPN2) knockdown on cytokine signaling in human
monocytic THP-1 cells treated with interferon-gamma (IFN-c)
and/or spermidine. THP-1 cells were transfected with either
nonspecific small interfering RNA (siRNA) or ptpn2 siRNA. The graphs
show secretion levels of (a) monocyte chemoattractant protein (MCP)-1,
and (b) interleukin (IL)-6 in THP-1 cells treated with IFN-c (1000 U/ml)
and/or spermidine (100 mM) for 24 h (n = 3). Data are expressed as fold
induction respect to untreated cells transfected with non-specific siRNA.
Significant differences compared to untreated (*** =p,0.001), IFN-c-
treated (#=p,0.05, ##=p,0.01), or IFN-c and spermidine co-treated
(xx = p,0.01) cells transfected with non-specific siRNA are indicated.
doi:10.1371/journal.pone.0073703.g007
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water (p,0.05; Figure 10b). Taken together, these results indicate
that spermidine treatment ameliorates DSS-induced intestinal
damage in mice.
Discussion
In the last decade, our understanding of the pathophysiological
mechanisms of IBD, as well as the immunologic and genetic
factors involved, has improved considerably. These advances have
resulted in the development of new treatments for patients
suffering from IBD [31]. However, since this new therapeutics,
mainly biological, often feature severe side effects, the need for
well-tolerable, but nevertheless effective treatment options is
obvious. Here, we have demonstrated that pharmacological
activation of PTPN2 by the polyamine spermidine ameliorates
inflammatory responses both in an in vitro as well as in an in vivo
model of inflammation. Our data have shown that spermidine
activates PTPN2, which plays a crucial role in controlling pro-
inflammatory signaling and gene expression events. Subsequently,
activation of PTPN2 results in decreased activation of pro-
inflammatory STAT1, STAT3 and p38 signal transmitters as well
as in decreased secretion of the pro-inflammatory cytokines IL-6
and MCP-1 in human monocytes. Even more interestingly,
administration of spermidine in a mouse model of colitis results
in a significant reduction in the disease severity, thereby validating
spermidine as a plausible new therapy option for the treatment of
IBD. Moreover, because spermidine is present in a broad variety
of foods and is also synthesized endogenously, its administration
seems to be a well-tolerable treatment option.
IFN-c is the prototypical macrophage-activating factor. In the
classical signaling pathway, IFN-c initiates its signal transduction
cascade via tyrosine phosphorylation of STAT1. Subsequently,
phosphorylated STAT1 dimerizes and the dimers bind to IFN-c-
stimulated response elements, inducing the transcription of various
genes [32]. We have demonstrated that spermidine treatment
Figure 8. Effects of spermidine treatment on weight curves and
endoscopic colonic damage in mice with DSS-induced acute
colitis. Female C57BL/6J-Clr mice received water (H2O), 150 ml 0.1 M
spermidine solution (SPMD), 2.5% DSS or 2.5% DSS plus 150 ml of 0.1 M
spermidine solution for 8 days. The panels show (a) weight curves
during colitis induction, (b) representative pictures of colonoscopy
performed on day 8, and (c) colonoscopic scoring. Results are
representative of two independent experiments with 6 mice in each
group. Asterisks indicate significant differences as assessed by Mann-
Whitney U post hoc test (* = p,0.05, ** = p,0.01).
doi:10.1371/journal.pone.0073703.g008
Figure 9. Effects of spermidine on epithelial damage and inflammation in mice with DSS-induced acute colitis. Female C57BL/6J-Clr
mice received water (a; H2O), 150 ml of 0.1 M spermidine solution (b; SPMD), 2.5% DSS (c) or 2.5% DSS plus 150 ml of 0.1 M spermidine solution (d) for
8 days. Panels a, b, c, and d show representative pictures from H&E stained histological sections. The graphs show severity of inflammatory cell
infiltration (e), epithelial damage (f) or combined scoring (g). Results are representative of two independent experiments with 6 mice in each group.
Asterisks indicate significant differences as assessed by Mann-Whitney U post hoc test (* = p,0.05).
doi:10.1371/journal.pone.0073703.g009
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markedly reduces IFN-c-induced phosphorylation of STAT1,
which leads to reduced secretion of the cytokine MCP-1 in a
PTPN2-dependent manner.
Besides the classical STAT1 signaling cascade, IFN-c activates
several other downstream pathways, including the p38 MAPK
signaling cascade [32]. One of the immune targets regulated by
the p38 MAPK signaling pathway is IL-6, a potent cytokine that
regulates immune and inflammatory responses. Due to its key role
in the pathogenesis of IBD, therapies targeting this cytokine are in
development [33]. We have found that spermidine treatment
significantly decreased the IFN-c-induced phosphorylation of p38
MAPK in a PTPN2-dependent manner. These results are in
accordance with previous data showing that PTPN2 negatively
regulates the IFN-c-induced signaling via p38 MAPK, including
IL-6 secretion [17]. Correlating with the decreased levels of IL-6,
we found reduced phosphorylation of STAT3 as well as lowered
mRNA expression of ICAM-1, both downstream molecules of the
p38 MAPK signaling cascade [34,35], in THP-1 cells treated with
spermidine and IFN-c compared to cells that were only treated
with IFN-c.
Both IL-6 and MCP-1 levels are increased in the intestinal
mucosa of IBD patients [36]. While IL-6 signaling is involved in
shaping the adaptive immune response [37], MCP-1 promotes
monocyte infiltration into inflamed tissues. In the gut MCP-1 also
inhibits the differentiation of monocytes into mature intestinal
macrophages (IMACs) with attenuated immune functions. In
active IBD, an increased fraction of over-activated and hyper-
reactive IMACs has been reported [38,39,40], which results in an
increased production of pro-inflammatory cytokines. Additionally,
elevated levels of MCP-1 can be found in the intestinal mucosa of
IBD patients. Therefore, reduced MCP-1 production upon
spermidine treatment might reduce the attraction of inflammatory
cells into the intestine and thereby decrease inflammatory
responses. Consistent with this hypothesis, spermidine treatment
also significantly reduced the number of inflammatory cells
infiltrating the mucosa of DSS treated mice.
In addition to the reduction of inflammatory cell infiltration into
the mucosa, spermidine treatment also significantly reduced
epithelial damage during DSS-mediated colitis. This might
partially be due to the fact that PTPN2, in addition to its
regulatory role on STAT and MAPK signaling in immune cells,
also plays an important protective role in intestinal epithelial cells,
maintaining barrier function and homeostasis during inflamma-
tion [18,19,25].
All cells contain substantial amounts of either spermidine or one
of the other polyamines, putrescine or spermine, which are
required for cell growth and proliferation [21,22]. Although diet is
the main source of polyamines, they can also be synthesized
endogenously. Interestingly, reduced levels of polyamines were
found in colonic samples from mice with induced chronic colitis
[41]. Moreover, lowered levels of ornithine decarboxylase, the
limiting enzyme in endogenous synthesis of polyamines, have been
reported in colonic mucosa from IBD patients [42], suggesting that
the lack of polyamines in inflamed tissue may aggravate the
disease. Our results support this notion, since spermidine
supplementation was able to significantly reduce inflammatory
responses in both an in vitro model of immune cell activation and
an in vivo model of intestinal inflammation.
In conclusion, we have shown that spermidine was able to
reduce inflammation by increasing the expression and activity of
PTPN2 in human THP-1 monocytes. As a consequence, PTPN2
negatively regulated the IFN-c-induced signaling pathways via
dephosphorylation of STAT1 and p38 MAPK, resulting in a
decrease in the secretion of pro-inflammatory cytokines. In mice
with DSS-induced acute colitis, spermidine treatment was able to
reduce disease severity, supporting the anti-inflammatory potential
of spermidine supplementation in vivo. Taken together, these
findings suggest that pharmacological activation of PTPN2 by
spermidine may represent a viable therapy to treat IBD and other
diseases featuring chronic intestinal inflammation. Further studies
to elucidate the clinical implications of these findings are therefore
warranted.
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